95 related articles for article (PubMed ID: 28259822)
1. DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin.
Li K; Mo C; Gong D; Chen Y; Huang Z; Li Y; Zhang J; Huang L; Li Y; Fuller-Pace FV; Lin P; Wei Y
Cancer Lett; 2017 Aug; 400():194-202. PubMed ID: 28259822
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
Frezzetti D; Caridi V; Marra L; Camerlingo R; D'Alessio A; Russo F; Dotolo S; Rachiglio AM; Esposito Abate R; Gallo M; Maiello MR; Morabito A; Normanno N; De Luca A
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732063
[TBL] [Abstract][Full Text] [Related]
3. ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.
Zhao L; Wang Y; Sun X; Zhang X; Simone N; He J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397056
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non-Small Cell Lung Cancer.
Guan S; Chen X; Chen Y; Xie W; Liang H; Zhu X; Yang Y; Fang W; Huang Y; Zhao H; Zhuang W; Liu S; Huang M; Wang X; Zhang L
Clin Cancer Res; 2022 Sep; 28(17):3770-3784. PubMed ID: 35695863
[TBL] [Abstract][Full Text] [Related]
5. Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.
Liu Z; Gao W
Toxicol Appl Pharmacol; 2017 Nov; 335():16-27. PubMed ID: 28942004
[TBL] [Abstract][Full Text] [Related]
6. The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression.
Ren S; Zhu Y; Wang S; Zhang Q; Zhang N; Zou X; Wei C; Wang Z
Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(1):81-90. PubMed ID: 36471952
[TBL] [Abstract][Full Text] [Related]
7. 5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.
Postiglione I; Chiaviello A; Aloj SM; Palumbo G
Cell Prolif; 2013 Aug; 46(4):382-95. PubMed ID: 23869760
[TBL] [Abstract][Full Text] [Related]
8. Integrative Analysis of Proteome and Ubiquitylome Reveals Unique Features of Lysosomal and Endocytic Pathways in Gefitinib-Resistant Non-Small Cell Lung Cancer Cells.
Li W; Wang H; Yang Y; Zhao T; Zhang Z; Tian Y; Shi Z; Peng X; Li F; Feng Y; Zhang L; Jiang G; Zhang F
Proteomics; 2018 Aug; 18(15):e1700388. PubMed ID: 29901268
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic strategies targeting bypass pathways and mitochondrial dysfunction to combat resistance to RET inhibitors in NSCLC.
Shiba-Ishii A; Isagawa T; Shiozawa T; Mato N; Nakagawa T; Takada Y; Hirai K; Hong J; Saitoh A; Takeda N; Niki T; Murakami Y; Matsubara D
Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167249. PubMed ID: 38768929
[TBL] [Abstract][Full Text] [Related]
10. Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer.
Zhang Z; Westover D; Tang Z; Liu Y; Sun J; Sun Y; Zhang R; Wang X; Zhou S; Hesilaiti N; Xia Q; Du Z
J Transl Med; 2024 Jun; 22(1):565. PubMed ID: 38872189
[TBL] [Abstract][Full Text] [Related]
11. Evodiamine potentiates cisplatin-induced cell death and overcomes cisplatin resistance in non-small-cell lung cancer by targeting SOX9-β-catenin axis.
Panda M; Biswal S; Biswal BK
Mol Biol Rep; 2024 Apr; 51(1):523. PubMed ID: 38630183
[TBL] [Abstract][Full Text] [Related]
12. Cytosolic malic enzyme and glucose-6-phosphate dehydrogenase modulate redox balance in NSCLC with acquired drug resistance.
Ran M; Zhou Y; Guo Y; Huang D; Zhang SL; Tam KY
FEBS J; 2023 Oct; 290(19):4792-4809. PubMed ID: 37410361
[TBL] [Abstract][Full Text] [Related]
13. Dual mechanisms regulate the nucleocytoplasmic localization of human DDX6.
Huang JH; Ku WC; Chen YC; Chang YL; Chu CY
Sci Rep; 2017 Feb; 7():42853. PubMed ID: 28216671
[TBL] [Abstract][Full Text] [Related]
14. Rational design of non-resistant targeted cancer therapies.
Martínez-Jiménez F; Overington JP; Al-Lazikani B; Marti-Renom MA
Sci Rep; 2017 Apr; 7():46632. PubMed ID: 28436422
[TBL] [Abstract][Full Text] [Related]
15. Editorial Note: Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of β-Catenin Signaling.
PLOS ONE Editors
PLoS One; 2024; 19(5):e0303600. PubMed ID: 38739616
[No Abstract] [Full Text] [Related]
16. Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells.
Nie L; Wang YN; Hsu JM; Hou J; Chu YY; Chan LC; Huo L; Wei Y; Deng R; Tang J; Hsu YH; Ko HW; Lim SO; Huang K; Chen MK; Chiu TJ; Cheng CC; Fang YF; Li CW; Goverdhan A; Wu HJ; Lee CC; Wang WL; Hsu J; Chiao P; Wang SC; Hung MC
Am J Cancer Res; 2023; 13(4):1209-1239. PubMed ID: 37168336
[TBL] [Abstract][Full Text] [Related]
17. β-catenin turnover is regulated by Nek10-mediated tyrosine phosphorylation in A549 lung adenocarcinoma cells.
Dutt P; Haider N; Mouaaz S; Podmore L; Stambolic V
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2300606121. PubMed ID: 38683979
[TBL] [Abstract][Full Text] [Related]
18. PSMD4 is a novel therapeutic target in chemoresistant colorectal cancer activated by cytoplasmic localization of Nrf2.
Cheng YM; Lin PL; Wu DW; Wang L; Huang CC; Lee H
Oncotarget; 2018 May; 9(41):26342-26352. PubMed ID: 29899863
[TBL] [Abstract][Full Text] [Related]
19. Measuring competitive exclusion in non-small cell lung cancer.
Farrokhian N; Maltas J; Dinh M; Durmaz A; Ellsworth P; Hitomi M; McClure E; Marusyk A; Kaznatcheev A; Scott JG
Sci Adv; 2022 Jul; 8(26):eabm7212. PubMed ID: 35776787
[TBL] [Abstract][Full Text] [Related]
20. Correction to 'DDX17 is required for efficient DSB repair at DNA: RNA hybrid deficient loci'.
Nucleic Acids Res; 2023 Oct; 51(19):10809-10810. PubMed ID: 37713635
[No Abstract] [Full Text] [Related]
[Next] [New Search]
